The complement system, which is made up of more than 30 serum and cell surface components, works with the innate and acquired immune systems to recognize and get rid of pathogens. Following the activation of the complement system, a series of events involving proteolysis and assembly lead to the cleavage of the third complement component (C3). The activation pathway refers to the cascade that leads to C3 cleavage. The classical, lectin, and alternative pathways are the three types of activation.
The complement cascade is a double-edged sword that causes phagocytosis and inflammation while also providing defense against viral and bacterial invasion. If complement is not properly controlled, it can cause significant pathological damage to erythrocytes (hemolysis), kidney basement membrane and attached endothelial and epithelial cells (nephritis), joint synovium (arthritis), and blood vessels (vasculitis).
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V74778 | POT-4 (AL-78898A) | 934461-40-2 | POT-4 (AL-78898A), a Compstatin analogue, is a potent inhibitor of complement factor C3 activation. |
|
V81176 | POT-4 TFA (AL-78898A TFA) | POT-4 TFA (AL-78898A TFA), a Compstatin analogue, is a potent inhibitor of complement factor C3 activation. | |
|
V74797 | Riliprubart (SAR 445088) | 2756228-76-7 | Riliprubart (SAR445088) is an anti-C1s humanized monoclonal antibody (mAb) that can inhibit activated C1s in the proximal part of the classical complement system. |
|
V4614 | SB290157 trifluoroacetate | 1140525-25-2 | SB290157 TFA, the trifluoroacetate salt ofSB-290157, is a novel, potent and selective antagonist of complement anaphylatoxin C3a receptor (IC50 = 200 nM) with the potential to be used in arthritis,diet-induced obesity, and metabolic dysfunction. |
|
V74798 | TLQP-21 | 869988-94-3 | TLQP-21 is a VGF-derived peptide with endocrine and endocrine properties and a potent G protein-coupled receptor complement 3a receptor 1 (C3aR1) agonist (EC50= mouse TLQP-21=10.3 μM; human TLQP-21=68.8 μM). |
|
V76411 | TLQP-21 TFA | TLQP-21 TFA is a VGF-derived peptide with endocrine and endocrine properties and is a potent G protein-coupled receptor complement 3a receptor 1 (C3aR1) agonist (EC50= mouse TLQP-21=10.3 μM; human TLQP-21=68.8 μM). | |
|
V106248 | tLyP-1 peptide | 1354801-55-0 | tLyP-1 peptide is a NRP-1 targeting peptide with an IC50 of 4 μM and an amino acid sequence of CGNKRTR. |
|
V74779 | Vemircopan (ALXN2050; ACH 0145228; ACH-5228) | 2086178-00-7 | Vemircopan (ALXN2050) is an orally bioactive complement factor D (FD) inhibitor. |
|
V94034 | Zilucoplan (PEG2) | Zilucoplan (PEG2) is a derivative of Zilucoplan in which the linker is substituted with PEG24. | |
|
V74781 | Zilucoplan (RA101495; RA3193) | 1841136-73-9 | Zilucoplan (RA101495; Zilbrysq)) is a 15-amino-acid macrocyclic peptide that is a potent inhibitor of complement component 5 (C5). |
|
V81774 | Zilucoplan TFA (RA101495 TFA; RA3193 TFA) | Zilucoplan TFA (RA101495; Zilbrysq) is a 15-amino-acid macrocyclic peptide that is a potent inhibitor of complement component 5 (C5). | |
|
V86827 | Zoracopan | 2243483-63-6 | Zoracopan is a selective inhibitor of complement factor D (CFD). |
|
V2514 | Iptacopan (LNP023) hydrochloride | 1646321-63-2 | Iptacopan (LNP-023;LNP023) HCl, the hydrochloride salt ofIptacopan,is an oral, potent and selective factor B inhibitor ( IC50 = 10 nM). |
|
V31830 | Compstatin | 206645-99-0 | Compstatin is a novel and potent 13-residue cyclic peptide acting as a potent inhibitor of thecomplement system C3with species specificity. |
|
V60096 | Phaseoloidin | 118555-82-1 | Phaseolin is a highly pure acid grain derived from tobacco caterpillars that helps plants resist lepidopteran herbivores. |
|
V60097 | Entadamide-A-β-D-glucopyranoside | 138916-58-2 | Entadamide-A-β-D-glucopyranoside is one of the major components of Phaseolus vulgaris seeds. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
